Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Qualigen Therapeutics ( (QLGN) ) just unveiled an announcement.
On September 19, 2025, Qualigen Therapeutics, Inc. announced a private placement offering involving the sale of its common and Series B convertible preferred stock, raising approximately $41 million. The investment, led by Faraday Future Intelligent Electric Inc., aims to support Qualigen’s transition into cryptocurrency and Web3-related business, with plans for a rebranding to CXC10. This strategic move is expected to enhance Qualigen’s market positioning by focusing on crypto and Web3, leveraging Faraday Future’s expertise and investment to drive growth and create synergies between the two companies.
Spark’s Take on QLGN Stock
According to Spark, TipRanks’ AI Analyst, QLGN is a Underperform.
Qualigen Therapeutics’ overall stock score is low due to significant financial challenges, including declining revenue, substantial losses, and financial instability. The bearish technical analysis further dampens the outlook. However, recent corporate events like strategic investments and leadership changes provide a slight positive outlook on future potential improvements.
To see Spark’s full report on QLGN stock, click here.
More about Qualigen Therapeutics
Average Trading Volume: 2,027,077
Technical Sentiment Signal: Sell
Current Market Cap: $7.02M
See more insights into QLGN stock on TipRanks’ Stock Analysis page.